Fulgent Genetics’ Post

MEDx recently showcased its innovative companion diagnostics solutions at the 2024 Medlab Asia & Asia Health in Thailand, one of Southeast Asia's influential medical events. At the event, MEDx presented a comprehensive range of advanced diagnostic solutions, including over 20 diagnostic kits. Highlighted products featured molecular platform-based PCR and NGS detection reagents, protein platform-based IHC detection reagents, and nucleic acid extraction reagents. These products meet diverse diagnostic needs and include CE-certified solutions for solid tumors (e.g., PD-L1, MSI, MMR, Claudin18.2, c-MET) and hematologic malignancies (e.g., BCR-ABL quantitative detection, MPN quadruple detection, blood tumor Ig/BCR rearrangement MRD detection), supporting companion diagnostics, drug guidance, and prognosis monitoring for precision medicine. #MedlabAsia #CompanionDiagnostics #PrecisionMedicine #MolecularDiagnostics #HealthcareInnovation #NGS #PCR #IHC #MedicalExhibition #CECertified #QimingPortfolio #QimingHealthcare

Have you seen our research poster on our new cell line development model, IndEx-2? 🧬 Our team have developed a powerful tool for the determination of precise antigen density activation thresholds for targeted immunotherapies. Dive into the most up-to-date information with our data-driven research poster. Grab your copy here: https://bit.ly/3t0uTf5 #Celllinedevelopment #IndEx-2 #Researchposter #Antibodytheraputics #Drugdiscovery #immunooncology

LucidQuest Views >>> How we helped a Top-10 BioPharma company enhance its strategic decision-making in the Sickle Cell Disease space. #Casestudies #casestudy Comment below! >>> lqventures.com

#News 🎉 April 17, Sanofi's frexalimab injection received implicit approval for two clinical trials in China for the treatment of adults with relapsing multiple sclerosis (RMS) and adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). The CD40–CD40L costimulatory pathway regulates adaptive and innate immune responses and has been implicated in the pathogenesis of multiple sclerosis. Frexalimab is a second-generation anti-CD40L monoclonal antibody being evaluated for the treatment of multiple sclerosis. 👉Check out our CD40/CD40L products: https://lnkd.in/gdxitXfR ☎ Fill in your demand and contact way! https://lnkd.in/gjxPUE88 #celllinedevelopment #cancertreatment #drugdiscovery #antibody

A Breakthrough in Alzheimer’s Disease Diagnosis: Roche and Eli Lilly’s pTau217 Plasma Biomarker Test The FDA has given breakthrough status to a diagnostic test developed by Roche and Eli Lilly for Alzheimer's disease. The pTau217 plasma biomarker test aims to provide a reliable and efficient means of identifying the disease. It can deliver swift and accurate results, enabling earlier intervention and more proactive management strategies. The test holds promise in revolutionizing diagnosis and expediting patient recruitment for clinical trials. It offers a non-invasive and accessible alternative to current diagnostic methods. The collaboration between Roche and Eli Lilly represents a beacon of hope for individuals affected by Alzheimer's and their loved ones. The test could also lead to advancements in personalized treatment approaches. For more details please click the link! https://lnkd.in/dXFDNqYz #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

Simultaneous analysis of endocrine inflammatory biomarkers is possible with multiplex #immunoassays 🥼 Learn how biomarker profiling is paving the way for novel diagnostic tools for #IPMN management. Merck Group MilliporeSigma Watch on-demand now → https://buff.ly/46QQHZh

#precisionmedicine, Or #targetedtherapy plays very critical role in advanced cancers day after day. our blood test #guardant360 enable guideline recommended complete genomic testing in order to help match patients to these #targetedtherapy, also monitor a patient's response to treatment, to help doctors refine treatment even further, which have made a radical difference in improving outcomes for patients battling advanced cancers. Hikma Pharmaceuticals Guardant Health Guardant Health AMEA #worldcancerday #wcd2024 #closethecaregap #guardant360 #liquidbiopsy #precisionmedicine

On Tuesday, November 28, #Novartis held its R&D Day 2023 (press release: https://bit.ly/40YMmRW / presentation: https://bit.ly/3T42krP) highlighting preparations for a Ph2b/3 study evaluating #YTB323 (#CD19 T-Charge CAR-T) in srSLE/LN while noting the data of 3 sentinel patients from the Ph1/2 trial (https://bit.ly/3GjfCJE) in #srSLE presented at #ACR23. Additionally, the company disclosed it is preparing trials for other B-cell-driven indications and suggested it could evaluate the potential of cell therapies in #MS. Celltelligence provides insights on Novartis’s progress in #autoimmunediseases while discussing the consequences that the FDA’s investigation into secondary T-cell malignancies after CAR-T infusion may have in the autoimmune disease space: https://bit.ly/CT-829509

Meet the Conigen Experts Have questions about how advanced proteins can be used as antigens or immunogens? Looking for soluble dimeric proteins to develop deeper insights into your research? Wondering how your specific membrane proteins can be generated as an immunogen?   Meet the Conigen team of experts at AAI booth #337 and get insights into the latest strategies empowering translational research and drug discovery. Let's push the boundaries of research together! https://lnkd.in/eyZgGVwu   #AAI2024 #Immunology #InnovateWithConigen #AdvancedProteins